NEW YORK, May 20, 2015 /PRNewswire/ -- As healthcare markets continue to evolve, drug developers and their supply chain partners are attempting to keep pace by addressing economic, market and therapeutic factors that increasingly revolve around how, when and where drugs are administered. This evolution is being driven by new and exciting options for patient care in the form of powerful drug therapies for treating diseases with improved outcomes and for treating diseases for which an effective treatment did not previously exist. Beyond oncology –where therapeutics continue to be supplied for administration via infusion – the majority of new non-oral drugs are being formulated for subcutaneous injection. Many of these drugs are indicated for chronic conditions, which because of the continuous need for dosing over time benefit significantly when patients can self-administer their medication. This report examines in detail the drugs, devices, therapeutics and markets that are set to change substantially over the remainder of the decade.
- Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
- Assesses key markets, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
- Provides market data and forecasts to 2022
- Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization
- Evaluates the impact of economic, technology, and regulatory factors
Read the full report: http://www.reportlinker.com/p02553109-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001